PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18459128-5	2009	The berberine-induced apoptosis of both the A549 and H1299 human lung cancer cells was associated with the disruption of mitochondrial membrane potential, reduction in the levels of Bcl-2, Bcl-xl while increase in Bax, Bak, and activation of caspase-3.	Berberine	4-13	BCL2 like 1	Homo sapiens	189-195	
18451495-4	2008	Combined treatment with berberine and cisplatin acted in concert to induce loss of mitochondrial membrane potential (Delta Psi m), release of cytochrome-c from mitochondria, and decreased expression of antiapoptotic Bcl-2, Bcl-x/L, resulting in activation of caspases and apoptosis.	Berberine	24-33	BCL2 like 1	Homo sapiens	223-230	
35526324-7	2022	Bcl-xL knockdown in AC16 cells and zebrafish demonstrated that Bcl-xL is required for BBR"s anti-apoptotic activity.	Berberine	86-89	BCL2 like 1	Homo sapiens	0-6	
27738318-8	2016	The expressions of Bcl-xL and Cyclind1 proteins were decreased, whereas the levels of cleavage of poly-ADP ribose polymerase (PARP) were considerably increased in the cell lines in response to berberine treatment.	Berberine	193-202	BCL2 like 1	Homo sapiens	19-25	
26503508-5	2015	Moreover, berberine activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bax, Bad, Apaf-1, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL.	Berberine	10-19	BCL2 like 1	Homo sapiens	245-251	
22850597-4	2012	In additional studies, treatment of QBC939 cells with different concentrations (10, 40, 80 muM) of berberine for 48 h resulted in a significant dose-dependent increase in apoptosis compared to the non-berberine-treated control, which was associated with an increased expression of pro-apoptotic protein Bax and decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xL.	Berberine	99-108	BCL2 like 1	Homo sapiens	369-375	
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	BCL2 like 1	Homo sapiens	105-111	
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	BCL2 like 1	Homo sapiens	260-267	
16189662-7	2006	Moreover, berberine induced the activation of caspase-8 and -3, and caused the cleavage of poly ADP-ribose polymerase (PARP) and the cytochrome c release, whereas the expression of Bid and anti-apoptosis factor Bcl-XL were decreased markedly.	Berberine	10-19	BCL2 like 1	Homo sapiens	211-217	
35526324-0	2022	Bcl-xL is required for the protective effects of low-dose berberine against doxorubicin-induced cardiotoxicity through blocking apoptosis and activating mitophagy-mediated ROS elimination.	Berberine	58-67	BCL2 like 1	Homo sapiens	0-6	
24173769-5	2014	Berberine suppressed CPT-11-induced NF-kappaB activation in a dose-dependent manner and enhanced chemosensitivity to CPT-11 by downregulating NF-kappaB activation of antiapoptotic genes, c-IAP1, c-IAP2, survivin and Bcl-xL.	Berberine	0-9	BCL2 like 1	Homo sapiens	216-222	
21527846-7	2011	Overexpression of bcl-xL by gene transfer prevented berberine-induced cell death, mitochondrial transmembrane potential loss, and cytochrome c and apoptosis-inducing factor release, but not ROS generation.	Berberine	52-61	BCL2 like 1	Homo sapiens	18-24